Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TP53 wild-type
i
Other names:
TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
7157
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
NTRK1-TP53 fusion (1)
NTRK1-TP53 fusion (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
PCR
Sensitive: A2 - Guideline
PCR
Sensitive
:
A2
PCR
Sensitive: A2 - Guideline
PCR
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
FCR
Sensitive: A2 - Guideline
FCR
Sensitive
:
A2
FCR
Sensitive: A2 - Guideline
FCR
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
chlorambucil
Sensitive: A2 - Guideline
chlorambucil
Sensitive
:
A2
chlorambucil
Sensitive: A2 - Guideline
chlorambucil
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
venetoclax + obinutuzumab
Sensitive
:
A2
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
venetoclax + obinutuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
CD20 inhibitor
Sensitive: A2 - Guideline
CD20 inhibitor
Sensitive
:
A2
CD20 inhibitor
Sensitive: A2 - Guideline
CD20 inhibitor
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
obinutuzumab + acalabrutinib
Sensitive
:
A2
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
obinutuzumab + acalabrutinib
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
ibrutinib + obinutuzumab
Sensitive: A2 - Guideline
ibrutinib + obinutuzumab
Sensitive
:
A2
ibrutinib + obinutuzumab
Sensitive: A2 - Guideline
ibrutinib + obinutuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
ibrutinib + rituximab
Sensitive: A2 - Guideline
ibrutinib + rituximab
Sensitive
:
A2
ibrutinib + rituximab
Sensitive: A2 - Guideline
ibrutinib + rituximab
Sensitive
:
A2
TP53 wild-type
Chronic Lymphocytic Leukemia
TP53 wild-type
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
TP53 wild-type
Chronic Lymphocytic Leukemia
TP53 wild-type
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
TP53 wild-type
Acute Myelogenous Leukemia
TP53 wild-type
Acute Myelogenous Leukemia
RG7388
Resistant: B - Late Trials
RG7388
Resistant
:
B
RG7388
Resistant: B - Late Trials
RG7388
Resistant
:
B
TP53 wild-type
Endometrial Cancer
TP53 wild-type
Endometrial Cancer
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
TP53 wild-type
Lymphoma
TP53 wild-type
Lymphoma
ALRN-6924
Sensitive: C2 – Inclusion Criteria
ALRN-6924
Sensitive
:
C2
ALRN-6924
Sensitive: C2 – Inclusion Criteria
ALRN-6924
Sensitive
:
C2
TP53 wild-type
Solid Tumor
TP53 wild-type
Solid Tumor
ALRN-6924
Sensitive: C2 – Inclusion Criteria
ALRN-6924
Sensitive
:
C2
ALRN-6924
Sensitive: C2 – Inclusion Criteria
ALRN-6924
Sensitive
:
C2
TP53 wild-type
Solid Tumor
TP53 wild-type
Solid Tumor
KRT-232
Sensitive: C2 – Inclusion Criteria
KRT-232
Sensitive
:
C2
KRT-232
Sensitive: C2 – Inclusion Criteria
KRT-232
Sensitive
:
C2
TP53 wild-type
Estrogen Receptor Positive Breast Cancer
TP53 wild-type
Estrogen Receptor Positive Breast Cancer
ALRN-6924
Sensitive: C2 – Inclusion Criteria
ALRN-6924
Sensitive
:
C2
ALRN-6924
Sensitive: C2 – Inclusion Criteria
ALRN-6924
Sensitive
:
C2
TP53 wild-type
Solid Tumor
TP53 wild-type
Solid Tumor
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
TP53 wild-type
Acute Myelogenous Leukemia
TP53 wild-type
Acute Myelogenous Leukemia
HDM201
Sensitive: C3 – Early Trials
HDM201
Sensitive
:
C3
HDM201
Sensitive: C3 – Early Trials
HDM201
Sensitive
:
C3
TP53 wild-type
Solid Tumor
TP53 wild-type
Solid Tumor
HDM201
Sensitive: C3 – Early Trials
HDM201
Sensitive
:
C3
HDM201
Sensitive: C3 – Early Trials
HDM201
Sensitive
:
C3
TP53 wild-type
Liposarcoma
TP53 wild-type
Liposarcoma
MK-8242
Sensitive: C3 – Early Trials
MK-8242
Sensitive
:
C3
MK-8242
Sensitive: C3 – Early Trials
MK-8242
Sensitive
:
C3
TP53 wild-type
Solid Tumor
TP53 wild-type
Solid Tumor
MK-8242
Sensitive: C3 – Early Trials
MK-8242
Sensitive
:
C3
MK-8242
Sensitive: C3 – Early Trials
MK-8242
Sensitive
:
C3
TP53 wild-type
Multiple Myeloma
TP53 wild-type
Multiple Myeloma
KRT-232
Sensitive: C3 – Early Trials
KRT-232
Sensitive
:
C3
KRT-232
Sensitive: C3 – Early Trials
KRT-232
Sensitive
:
C3
TP53 wild-type
Liposarcoma
TP53 wild-type
Liposarcoma
HDM201
Sensitive: C3 – Early Trials
HDM201
Sensitive
:
C3
HDM201
Sensitive: C3 – Early Trials
HDM201
Sensitive
:
C3
TP53 wild-type
Merkel Cell Carcinoma
TP53 wild-type
Merkel Cell Carcinoma
KRT-232
Sensitive: C3 – Early Trials
KRT-232
Sensitive
:
C3
KRT-232
Sensitive: C3 – Early Trials
KRT-232
Sensitive
:
C3
TP53 wild-type
Melanoma
TP53 wild-type
Melanoma
trametinib + dabrafenib + KRT-232
Sensitive: C3 – Early Trials
trametinib + dabrafenib + KRT-232
Sensitive
:
C3
trametinib + dabrafenib + KRT-232
Sensitive: C3 – Early Trials
trametinib + dabrafenib + KRT-232
Sensitive
:
C3
TP53 wild-type
Acute Myelogenous Leukemia
TP53 wild-type
Acute Myelogenous Leukemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
TP53 wild-type
Myelodysplastic Syndrome
TP53 wild-type
Myelodysplastic Syndrome
ONO-7913
Sensitive: C3 – Early Trials
ONO-7913
Sensitive
:
C3
ONO-7913
Sensitive: C3 – Early Trials
ONO-7913
Sensitive
:
C3
TP53 wild-type
Salivary Gland Cancer
TP53 wild-type
Salivary Gland Cancer
APG-115
Sensitive: C3 – Early Trials
APG-115
Sensitive
:
C3
APG-115
Sensitive: C3 – Early Trials
APG-115
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login